Spirox

What Spirox does

Spirox is a medical device company founded in 2011 that develops solutions for patients suffering from nasal obstruction, with its corporate headquarters listed in Menlo Park, California. The company's product focus centers on implantable devices intended to improve nasal airflow, addressing a condition (nasal valve collapse or related obstruction pathologies) typically treated by otolaryngologists (ENT surgeons). The company is classified as for-profit and private, though a 2026 news signal suggests possible Taiwan stock-market activity, indicating a potential Asia-Pacific capital-markets or affiliate footprint that is not fully reconciled with the US corporate base.

Spirox has raised approximately $71.5 million in venture capital across four disclosed funding rounds between 2011 and 2016, anchored by healthcare-specialist investors including Aisling Capital, Venrock, HealthQuest Capital, and a late-stage crossover from Kohlberg Kravis Roberts & Co. (KKR). The Series C round in March 2016 ($45M, KKR-led) was the largest capital event disclosed. The company operates with 11–50 employees and is reported as actively operating, though its primary website (spiroxmed.com) is currently inaccessible due to a TLS/certificate configuration error pointing to a generic Odoo wildcard certificate, which limits primary-source verification of current product portfolio, commercial metrics, and pipeline.

The company's revenue model, pricing structure, distribution channels, customer segments, and product-level technical specifications were not disclosed in available sources. Similarly, no patents, certifications, regulatory milestones (e.g., FDA clearances), partnerships, management team, or product launches were surfaced in the data set. The current business model must therefore be inferred from the medical-device category context: B2B sales to hospitals and ENT specialty practices via direct sales reps or specialty distributors, with reimbursement driven by CPT coding for nasal valve procedures. Given the data gaps, a complete picture of Spirox's commercial scale and product maturity cannot be confirmed from the input alone.

Name

Spirox

Website

https://spiroxmed.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Spirox is a venture-backed medical device company founded in 2011 that develops implantable solutions for patients with nasal obstruction, serving otolaryngologists and the broader ENT surgical market. It has raised approximately $71.5M from healthcare-focused investors including KKR and Venrock.

Ownership category

akta.pro rank

Product category

ENT Medical Devices

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• Medical devices
• Nasal obstruction treatment
• ENT implants
• Airway restoration devices
• Minimally invasive surgery

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

Spirox is a medical device company that develops and sells devices intended to improve the quality of life for patients suffering from nasal obstruction. The company's products target the ear, nose, and throat (ENT) clinical specialty and are designed for use by healthcare providers treating nasal airway blockage.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• Intersect ENT: Developer of the PROPEL sinus implant, a bioabsorbable steroid-eluting device for sinus surgery patients — directly comparable to Spirox's absorbable nasal implant strategy targeting ENT surgeons and patients with nasal/sinus conditions. Acquired by Medtronic in 2022.
• Entellus Medical: Developed minimally invasive ENT devices including balloon sinuplasty systems for treating nasal obstruction and chronic sinusitis — overlapping patient population and clinical setting with Spirox's nasal obstruction franchise. Acquired by Stryker in 2018.
• Acclarent: Pioneer in balloon sinuplasty and ENT navigation systems for nasal and sinus procedures; comparable because it serves the same ENT surgeons treating nasal obstruction and chronic sinusitis with similar minimally invasive device approaches. A Johnson & Johnson company.

Emerging players

• Aerin Medical: Emerging ENT-focused company developing devices for nasal airway obstruction (VivAer) and chronic rhinitis — competes in the same nasal obstruction patient segment as Spirox with a non-implant energy-based approach.

Broad incumbents

• Stryker: Large diversified medical device company with a significant ENT/neurotechnology and surgical navigation franchise (including acquired Entellus Medical). Comparable as a broad incumbent operating in Spirox's addressable ENT/sinus space.
• Medtronic: Global medical device leader with a strong ENT, sinus, and cranial surgery portfolio that absorbed Intersect ENT. Comparable as a broad incumbent with overlapping nasal/sinus device capabilities.
• Olympus: Major medical device company with a dedicated ENT surgical solutions portfolio including rigid endoscopy, imaging, and powered instrumentation — addresses the same ENT surgical customer base as Spirox.
• Smith & Nephew: Global medical device company with ear, nose, and throat repair and reconstruction products — serves the same ENT surgeon customer base treating nasal obstruction and related conditions.
• KARL STORZ: Family-owned medical device leader specializing in endoscopy for ENT, including rigid and flexible endoscopes and instruments used in nasal/sinus surgery — serves overlapping clinical use cases and customer base.

Others

• Cook Medical: Privately held medical device manufacturer with ENT/sinus product lines and broader specialty device portfolio — adjacent participant in the same physician customer base, relevant as a comparable mid-size medtech player.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Customer concentration

• LinkedInlinkedin.com/company/spirox-inc-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spirox